Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK’s vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials—the best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas “at a very reasonable price”.
To continue reading, today with our introductory offers
Advertisement
More from New Å®ÉúСÊÓƵ
Explore the latest news, articles and features
Popular articles
Trending New Å®ÉúСÊÓƵ articles
1
The Selfish Gene at 50: Why Dawkins’s evolution classic still holds up
2
We may finally know why dinosaurs like T. rex evolved tiny arms
3
Mystery of the ancient giant stone jars of Laos may have been solved
4
The ‘doomsday’ glacier’s giant ice shelf is about to break away
5
Solar farm on the ocean outperforms land-based solar in Taiwan
6
The distant world that is our best hope of finding alien life
7
CAR T-cell therapy bolstered by stiffening up cancer cells first
8
How I used psychology to come back from the worst year of my life
9
Can we harness quantum effects to create a new kind of healthcare?
10
Why autism pioneer Uta Frith wants to dismantle the spectrum
